Novo Nordisk NVO, +1.48% NOVO.B, +1.93% said Thursday it has entered research collaboration agreements with Omega Therapeutics Inc. OMGA, -8.08% and Cellarity on new treatments for obesity management. The Danish developer of weight-loss drugs Ozempic and Wegovy said the Omega collaboration will leverage its proprietary platform technology to develop an epigenomic controller that aims to enhance metabolic activity. The Cellarity collaboration aims to discover biological drivers of metabolic dysfunction-assoc ...